Background: Hepatic arterioportal fistulas are rare, abnormal, direct communications between hepatic artery and portal venous system. Treatment options shifted from surgery to endovascular interventions. Catheterization may be challenging. We report a case of a hepatic arterioportal fistula treated successfuly with Amplatzer Vascular Plug II via percutaneous transhepatic hepatic artery access after failed transfemoral approach.

Case Presentation: 58 year old woman presented with right heart failure, kidney insufficiency and massive ascites related to portal hypertension caused by hepatic arterioportal fistula. She had a history of previous abdominal surgery. Colour Doppler ultrasound and computed tomography revealed a giant portal vein aneurysm related to large hepatic areterioportal fistula. Endovascular treatment was planned. Catheterization of the hepatic artery could not be realized due to severe tortuosity and angulation of the celiac artery and its branches. Access to the hepatic artery was obtained directly via percutaneous transhepatic route and fistula site was embolized with Amplatzer Vascular Plug II and coils. Immediate thrombosis of the aneurysm sac and draining portal vein was observed. Patients clinical status improved dramatically.

Conclusion: Transcatheter embolization is the first choice of the treatment of hepatic arterioportal fistulas but the type of the therapy should be tailored to the patient and interventional radiologist should decide the access site depending on his own experience if the routine endovascular access can not be obtained.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966339PMC
http://dx.doi.org/10.1186/s42155-019-0084-yDOI Listing

Publication Analysis

Top Keywords

hepatic arterioportal
20
hepatic artery
20
arterioportal fistula
12
portal vein
12
percutaneous transhepatic
12
hepatic
11
endovascular treatment
8
treatment hepatic
8
giant portal
8
vein aneurysm
8

Similar Publications

BACKGROUND Arterioportal fistulas (APFs) are abnormal connections between the arterial and portal venous systems, leading to portal hypertension (PH) and symptoms such as gastrointestinal bleeding, splenomegaly, and hepatic pain. Symptoms typically appear by the age of 2 years in about 75% of cases. CASE REPORT A 7-year-old boy with an asymptomatic APF developed life-threatening complications following a Clostridium difficile infection.

View Article and Find Full Text PDF
Article Synopsis
  • Robotic vascular resection and reconstruction is complex, and portal vein arterialization (PVA) is an effective alternative when the hepatic artery can't be repaired, enhancing liver oxygen supply and promoting regeneration.
  • A case study describes a 52-year-old man with cholangiocarcinoma who underwent robotic left-liver-first surgery, but sustained an artery injury, leading to the use of PVA for successful artery-portal vein anastomosis.
  • The surgery lasted 490 minutes with a blood loss of about 300 mL, and although there was a bile leak post-surgery, the patient recovered without experiencing liver failure.
View Article and Find Full Text PDF

Background And Objectives: Transarterial chemoembolization (TACE) and I seed implantation are methods used to treat hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), PVTT often associated with arterioportal shunts(APS), there are few reports on the combined use of TACE and I seed implantation for such patients. This study aimed to evaluate the efficacy and safety of TACE combined with PVTT I seed implantation in the treatment of HCC patients with APS.

Methods: Forty-two patients diagnosed with HCC combined with PVTT and APS between January 2020 and December 2021 were included.

View Article and Find Full Text PDF

Objective: To evaluate the efficacy and safety of drug eluting bead transarterial chemoembolization (D-TACE) combined with apatinib/camrelizumab in patients with advanced hepatocellular carcinoma (HCC) and hepatic arterioportal shunts (APSs).

Methods: From January 2021 to December 2022, the consecutive medical records of patients with advanced HCC and APS receiving D-TACE combined with apatinib/camrelizumab were reviewed for eligibility. Overall survival (OS), progression-free survival (PFS), tumour response, and adverse events (AEs) were assessed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!